V.Active Projects
From the lab to commercial-ready.
A working portfolio of translational projects — co-developed with Australian universities, Chinese research groups, and industry partners. Each is structured to move from research validation through pilot manufacturing to compliant product.
P / 01AI-Enabled Modular Building SystemsShelter
Smart Energy Modular Buildings — AI-enabled, low-carbon, scalable.
A scalable, AI-enabled, carbon-enhanced modular building system integrating carbon-based phase change materials (PCM), building-integrated photovoltaics (BIPV), battery storage and an AI-driven Building Energy Management System (BEMS) into prefabricated panels. Targets a 30–50% reduction in operational energy demand and 20–40 kWh/m²/year on-site renewable generation, with multi-state real-world demonstrations.
TRL 3 → 5CRC-P PathwayUSydRMITPromodALTASisley Prestige HomesSotastack
P / 02NMN · NAD+ Precursor CapsulesBiotech
Enzymatic NMN at scale — manufactured in Australia.
Natural Biotech Pty Ltd's flagship 12,000 mg NMNs capsule line, manufactured in South Australia under a contracted research relationship with the University of Adelaide. Enzyme-catalysed synthesis pathway designed for purity, cost-efficient scale-up and a globally distributable supplement format addressing the well-documented age-linked decline in NAD+.
Commercial · LiveMade in AustraliaUniversity of AdelaideNatural Biotech Pty Ltd
P / 03Specialty Plasmalogen SynthesisBiotech
High-purity plasmalogens for cognitive health.
A specialty phospholipid R&D programme developing high-purity plasmalogen (Pls) monomers via microbial enzymatic synthesis — addressing the membrane fluidity and free-radical-scavenging pathways implicated in age-related cognitive decline. Pre-clinical pipeline targeting functional food, supplement and pharmaceutical formats; clinical Phase 1–3 pathway under design.
Pre-clinicalFunctional Food + PharmaZhejiang University (Prof. Tian)Natural Biotech
P / 04Tuna-Derived Anserine PeptidesBiotech
Marine peptides for uric acid and anti-fatigue.
Patented (ZL202211553053.7) enzymatic process producing bluefin tuna-derived small peptides containing 2–10% anserine — a buffering dipeptide with demonstrated XOD/ADA-pathway inhibition. Targets the hyperuricemia (180M+ patients in China) and anti-fatigue specialty-food categories with a clinically informed natural alternative to allopurinol.
Patent · ZL202211553053.7Specialty FoodLan Kun Marine Biotech
P / 05Alpha Shaper · AlbioBiotech
Carbohydrate-absorption chewable tablets.
A 100% Australian-owned chewable tablet line developed under the Albio brand. Pure plant extracts inhibit carbohydrate absorption to support a sugar-controlled metabolic pathway — positioned as a clinically considered alternative to dieting, stimulant fat-burners and surgical interventions across the weight-management category.
Commercial · Live100% Australian OwnedGMP · H&L · Australian Made
P / 06Sustainable Construction MaterialsShelter
Compliant panel composites for net-zero housing delivery.
Promod's standing R&D function develops sustainable building material specifications, fire- and thermal-performance pathways, and IP suitable for prefabricated and standardised housing delivery — validated through accredited third-party testing (CSIRO Infrastructure Technologies, Warringtonfire Australia) and academic collaboration.
Specifications + ComplianceUniversity of MelbourneUniversity of SydneyPromod
